TheStreet) -- Fans of FDA advisory panels have a riveting week of action ahead.
Starting Tuesday morning, outside experts invited by FDA will weigh the risks and benefits of three different drugs on three consecutive days. The recommendations that emerge from these FDA advisory panels will factor into the agency's approval decisions.
(NPSP - Get Report) brings Gattex, a treatment for short bowel syndrome, in front of the Gastrointestinal Drugs Advisory Committee on Tuesday Oct. 16.
On Wednesday Oct. 17, the Endocrinologic and Metabolic Drugs Advisory Committee convenes for two days of hearings to review drugs aimed at helping patients with a rare genetic disorder that causes extremely high levels of cholesterol to accumulate in their blood.
The panel will review
(AEGR - Get Report)
lomitapide on Wednesday followed on Thursday by mipomersen, a drug developed by
(ISIS - Get Report)
and the Genzyme unit of
(SNY - Get Report)
I will be live-blogging all three FDA advisory panels with play-by-play and analysis in real time from the opening gavels all the way through the final votes.
You can sign up for email reminders for each panel below.
Short bowel syndrome (SBS) is a chronic and disabling condition that strikes people, who for various reasons including Crohn's disease, have about 50% of their lower intestines surgically removed. A majority of patients can adapt to lead normal lives. A smaller group of SBS patients never recover full functionality of their lower intestines, and a result, must spend the rest of their lives attached to an intravenous parenteral nutrition bag that provides the liquid nutrients they need to survive.
Gattex is an analogue of GLP-2, a protein involved with intestinal growth and function. Administered via a shot under the skin, Gattex is designed to boost the ability of the intestine to absorb nutrients.
On Friday, NPS Pharma shares rose 19% to $10.86 due to a largely positive FDA review of Gattex released ahead of Tuesday's panel. The FDA appears to be concur with NPS Pharma that Gattex provides a clinically meaningful benefit for SBS patients. The agency also appears unconcerned about three cases of cancer reported in patients treated with Gattex.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts